On Monday, analysts at Morgan Stanley reiterated their Overweight rating on Gilead Sciences, Inc. (NASDAQ:GILD), while ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Median PFS increased from 1.94 months with single-agent fulvestrant to 5.32 months with the addition of ipatasertib. Patients ...

Herpes simplex virus type 1 (HSV-1) is associated with an increased risk for Alzheimer disease (AD) based on real-world data from the United States.

TWN calls for urgent need of stronger scrutiny in granting patents to avoid evergreening: Our Bureau, New Delhi Tuesday, June 3, 2025, 08:00 Hrs [IST] Third World Network (TWN), a ...

Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target.

Shares of Gilead Sciences Inc. GILD slid 1.06% to $108.91 Monday, on what proved to be an all-around favorable trading ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

This edition of Market Factors includes a thematic investing approach uncovering stocks that outperform. New stresses in the ...

Gilead Sciences’ SuYvonne Bell explains how she’s rethinking fleet operations for sustainability, safety, and competitiveness in a post-COVID era.

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...